Royal Bank Of Canada restated their buy rating on shares of Boston Scientific Corporation (NYSE:BSX) in a research report report published on Tuesday, November 7th. The brokerage currently has a $31.00 price target on the medical equipment provider’s stock.
A number of other research analysts have also recently weighed in on the company. Stifel Nicolaus restated a buy rating and issued a $32.00 price target on shares of Boston Scientific in a research report on Sunday, July 30th. Jefferies Group LLC reissued a hold rating on shares of Boston Scientific in a research report on Thursday, September 7th. BMO Capital Markets reissued a buy rating and set a $30.00 price target on shares of Boston Scientific in a research report on Friday, October 13th. Canaccord Genuity initiated coverage on Boston Scientific in a research report on Tuesday, October 24th. They set a buy rating and a $36.00 price target on the stock. Finally, Zacks Investment Research lowered Boston Scientific from a hold rating to a sell rating in a research report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific currently has a consensus rating of Buy and a consensus target price of $30.77.
Shares of Boston Scientific (BSX) traded up $0.19 during mid-day trading on Tuesday, reaching $28.66. The company’s stock had a trading volume of 1,240,000 shares, compared to its average volume of 6,469,465. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific has a 12 month low of $19.67 and a 12 month high of $29.93. The firm has a market cap of $39,355.80, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.21 and a beta of 1.00.
In other news, SVP Maulik Nanavaty sold 57,031 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $27.28, for a total value of $1,555,805.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Supratim Bose sold 347,137 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total value of $10,108,629.44. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock valued at $14,581,669 over the last quarter. Company insiders own 0.74% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of BSX. Comerica Securities Inc. boosted its stake in Boston Scientific by 0.9% during the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock valued at $318,000 after purchasing an additional 99 shares during the period. ETRADE Capital Management LLC increased its holdings in Boston Scientific by 1.7% during the second quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock valued at $279,000 after buying an additional 171 shares during the last quarter. BB&T Corp increased its holdings in Boston Scientific by 2.8% during the second quarter. BB&T Corp now owns 12,926 shares of the medical equipment provider’s stock valued at $359,000 after buying an additional 349 shares during the last quarter. Krilogy Financial LLC increased its holdings in Boston Scientific by 5.9% during the second quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock valued at $213,000 after buying an additional 430 shares during the last quarter. Finally, Wetherby Asset Management Inc. increased its holdings in Boston Scientific by 3.9% during the second quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock valued at $382,000 after buying an additional 523 shares during the last quarter. Hedge funds and other institutional investors own 90.68% of the company’s stock.
WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/boston-scientific-corporation-bsx-stock-rating-reaffirmed-by-royal-bank-of-canada/1763218.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with our FREE daily email newsletter.